Telendo is among the 17 deeptech startups selected by EIT Health in May 2025 to join its Venture Builder program, dedicated to accelerating research-driven health technologies across Europe.<\/p>\n<\/div>
A program dedicated to industrializing deeptech innovations in healthcare<\/h4><\/div>Launched by EIT Health, one of Europe\u2019s leading health innovation networks, the Venture Builder program supports high-potential deeptech projects that often struggle to bridge the gap between academic proof of concept and market entry. This stage, frequently described as the \u201cno man\u2019s land\u201d or \u201cvalley of death,\u201d slows the valorization of research results and the creation of concrete solutions for patients.<\/p>\n
The program provides selected startups with individualized support in:<\/p>\n<\/div>
- <\/i><\/span>regulatory strategy and market access<\/div><\/li>
- <\/i><\/span>\n
industrial planning<\/p>\n<\/div><\/li>
- <\/i><\/span>\n
clinical validation and pilot studies<\/p>\n<\/div><\/li>
- <\/i><\/span>\n
commercial development and European partnerships<\/p>\n<\/div><\/li><\/ul><\/div><\/div><\/div><\/div>
![](\"https:\/\/telendo.com\/wp-content\/uploads\/2023\/09\/EIT-Health.webp\" "\\"EIT-Health\\"")
<\/span><\/div><\/div><\/div>![](\"https:\/\/telendo.com\/wp-content\/uploads\/2025\/05\/IMIMWebsite64.png\" "\\"IMIM+Website+(64)\\"")
<\/span><\/div><\/div><\/div>This selection validates Telendo\u2019s mission to structure visual information in digestive endoscopy to improve diagnosis, patient follow-up, and clinical traceability. After several years of academic research and a technological maturation phase in France, Telendo is now entering a phase of active industrialization.<\/p>\n
This European recognition adds to the institutional and clinical support already obtained in France and will accelerate regulatory structuring and the deployment of the solution at the European scale.<\/p>\n<\/div>
Launched by EIT Health, one of Europe\u2019s leading health innovation networks, the Venture Builder program supports high-potential deeptech projects that often struggle to bridge the gap between academic proof of concept and market entry. This stage, frequently described as the \u201cno man\u2019s land\u201d or \u201cvalley of death,\u201d slows the valorization of research results and the creation of concrete solutions for patients.<\/p>\n
The program provides selected startups with individualized support in:<\/p>\n<\/div>
- <\/i><\/span>regulatory strategy and market access<\/div><\/li>
- <\/i><\/span>
\nindustrial planning<\/p>\n<\/div><\/li>
- <\/i><\/span>
\nclinical validation and pilot studies<\/p>\n<\/div><\/li>
- <\/i><\/span>
\ncommercial development and European partnerships<\/p>\n<\/div><\/li><\/ul><\/div><\/div><\/div><\/div>
<\/span><\/div><\/div><\/div><\/span><\/div><\/div><\/div>This selection validates Telendo\u2019s mission to structure visual information in digestive endoscopy to improve diagnosis, patient follow-up, and clinical traceability. After several years of academic research and a technological maturation phase in France, Telendo is now entering a phase of active industrialization.<\/p>\n
This European recognition adds to the institutional and clinical support already obtained in France and will accelerate regulatory structuring and the deployment of the solution at the European scale.<\/p>\n<\/div>
- <\/i><\/span>